GO
Loading...

Enter multiple symbols separated by commas

Achillion Pharmaceuticals Inc

More

  • May 20- U.S. healthcare conglomerate Johnson& Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines. J&J said it would file for approval of daratumumab for the blood cancer multiple myeloma in the United...

  • 19)@ (Corrects paragraphs 2 and 3 to say J&J's $1.1 billion potential payments include equity investment of $225 million and are not in addition to the $1.1 billion). May 19 (Reuters)- Achillion Pharmaceuticals Inc said it will collaborate with Johnson& Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and...

  • NEW YORK, May 20- U.S. healthcare conglomerate Johnson& Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines. J&J said it would file for approval of the experimental drug daratumumab for the blood cancer...

  • May 19- Achillion Pharmaceuticals Inc said it will collaborate with Johnson& Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and shorten treatment time. Johnson& Johnson will also invest $225 million in Achillion in return for about 18.4 million unregistered shares at $12.25 per share.

  • Achillion partners with J&J to develop hep C drugs Tuesday, 19 May 2015 | 4:29 PM ET

    May 19- Achillion Pharmaceuticals Inc said it will collaborate with Johnson& Johnson to develop and market one or more of its hepatitis C drugs. Achillion will be eligible for milestone payments of up to $1.1 billion related to the development, regulatory approval and sales of the drugs. Johnson& Johnson will also invest $225 million in Achillion in return for...

  • Cramer Remix: You need to see this Apple news Tuesday, 10 Feb 2015 | 7:11 PM ET
    Jim Cramer on the set of Mad Money

    Apple made news after the close and “Mad Money’s” Jim Cramer is clueing you in.

  • *All-Achillion combination could rival Gilead, AbbVie treatments. Achillion's shares rose as much as 19 percent to $12.85 on Monday on investor's hopes that an all-Achillion combination could be as effective as Gilead's and AbbVie Inc's current therapies. The estimated $20 billion market for hepatitis C drugs has developed at a lightning pace in recent...

  • *Qualcomm up, nears deal with China on antitrust dispute. "China is a negative and Greece is a negative, certainly Greece is something investors have lived with for a while and it's not a huge surprise," said Rick Meckler, president of investment firm LibertyView Capital Management in Jersey City, New Jersey. On Monday, European Commission President Jean-Claude...

  • *Qualcomm near deal with China on antitrust dispute, shares climb. On Monday, European Commission President Jean-Claude Juncker said Greeks should not expect the euro zone to accept the latest terms proposed by Greece. "We are seeing heightened nervousness over the Greek elections and the policies that could make or break its EU membership," said Andre Bakhos,...

  • *Qualcomm near deal with China on antitrust dispute. NEW YORK, Feb 9- U.S. stocks were poised for a lower open on Monday, on the heels of disappointing economic data out of China and signs of rising tensions surrounding Greek debt negotiations. "We are seeing heightened nervousness over the Greek elections and the policies that could make or break its EU membership,"...

  • Feb 9- Achillion Pharmaceuticals Inc said its experimental hepatitis C drug, when used in combination with Gilead Sciences Inc's Sovaldi, eradicated signs of the virus after six weeks of therapy, sending its shares up before the opening bell. If the combination of Sovaldi and Achillion's ACH-3102 continues to show this level of effectiveness, the treatment...

  • Feb 4- Investors reassessed their growth expectations for the red-hot biotechnology sector on Wednesday after Gilead Sciences Inc warned of steep drug discounts, but a number of fund managers seemed prepared to stick with the stocks. Gilead disclosed late on Tuesday that it would give health insurers and pharmacy benefit managers discounts of 46 percent on...

  • Wednesday's midday movers: Comcast, Apple & more Wednesday, 4 Feb 2015 | 12:16 PM ET
    Traders on the floor of the New York Stock Exchange.

    Take a look at some of Wednesday's midday movers:

  • Pricing wars heat up over hepatitis C drugs Wednesday, 4 Feb 2015 | 12:13 PM ET
    A researcher works on a hepatitis C virus drug at Gilead Sciences lab in Foster City, Calif.

    Discounts on Gilead's hepatitis C drugs this year will be 46 percent, way more than investors and analysts expected.

  • Gilead drags healthcare shares down on drug price worries Wednesday, 4 Feb 2015 | 11:38 AM ET

    Feb 4- Healthcare shares plunged on Wednesday, lead by biotechnology stocks, after Gilead Sciences Inc said it gave health insurers steeper-than-expected discounts on its hepatitis C drugs, fueling worries that the broader sector would face increasing price pressure. Gilead weighed most heavily on the biotechnology sector with a 8.9 percent drop in its...

  • Lightning Round: This one has too much exposure Tuesday, 27 Jan 2015 | 7:23 PM ET
    Mad Money Lightning Round

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Cramer Remix: Buy into this weakness Tuesday, 6 Jan 2015 | 7:03 PM ET
    Jim Cramer on Mad Money.

    The recent selloffs have been ugly, but "Mad Money" host Jim Cramer thinks you can buy these stocks into the red arrows.

  • Dow ends at record after six-day win streak Wednesday, 24 Dec 2014 | 1:26 PM ET
    Trader Peter Tuchman wears a "Dow 18,000" cap as he works on the floor of the New York Stock Exchange in New York, December 23, 2014.

    Stocks drifted higher Wednesday, a day after the Dow rose above 18,000 for the first time.

  • Futures signal Wall Street's record rise to continue Wednesday, 24 Dec 2014 | 8:43 AM ET
    Santa Claus at the New York Stock Exchange

    U.S. stock index futures signaled a higher open on Wednesday, with volumes expected to be thin as markets close early for the Christmas holiday.

  • Midday movers: Hertz, Ocwen, Coca-Cola & more Tuesday, 23 Dec 2014 | 12:57 PM ET

    Some of Tuesday's midday movers: